search
Back to results

Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study (RASTA-AF)

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Aggressive Risk Factor Control
Standard of Care
Sponsored by
Nova Scotia Health Authority
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Atrial Fibrillation focused on measuring Risk Factor Modification, Catheter ablation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with symptomatic (CCS-SAF ≥2) recurrent paroxysmal or persistent nonvalvular atrial fibrillation despite rate control, desiring catheter ablation AND
  • one of : BMI>27, BP>140/90 or history of hypertension, alcohol use > recommended limit, current smoking, diabetes with HgA1C>7%, physical inactivity (<150 minutes/week).

(Definitions: Recurrent paroxysmal - at least 4 episodes of symptomatic AF in the prior 6 months, with or without cardioversion; Persistent AF lasting greater than 7 days but less than 3 years; AF must be documented on a Holter, rhythm strip or electrocardiogram within the last 24 months.)

Exclusion Criteria:

  • Permanent AF (AF lasting > 3 years)
  • Prior catheter ablation for AF
  • Left ventricular ejection fraction <30%
  • Left atrial size > 5.5 cm
  • NYHA IV heart failure
  • Participation in a cardiac rehabilitation program within the last year
  • Currently performing exercise training 150 minutes/week of moderate to vigorous physical activity
  • Unable to exercise
  • Unable to give informed consent
  • Other noncardiovascular medical condition making 1 year survival unlikely

Sites / Locations

  • QE II Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Aggressive Risk Factor Control

Standard of Care

Arm Description

Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management

All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.

Outcomes

Primary Outcome Measures

adherence to the risk factor intervention
80% compliance to each of the components: 150 minutes exercise/week, BP target as per CHEP guidelines, alcohol limits, smoking cessation, and sleep apnea therapy, hemoglobin A1C<6.5% at the end of follow up. If 80% of individuals can reach these 80% of the time, the adherence criteria will be met.

Secondary Outcome Measures

Feasibility of recruitment
Recruitment of ≥2.8 patients/center/month over three centers, thereby completing recruitment in 6 months

Full Information

First Posted
May 31, 2017
Last Updated
December 17, 2019
Sponsor
Nova Scotia Health Authority
Collaborators
Canadian Cardiovascular Society
search

1. Study Identification

Unique Protocol Identification Number
NCT03186976
Brief Title
Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study
Acronym
RASTA-AF
Official Title
Reversal of Atrial Substrate to Prevent Atrial Fibrillation - A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
October 31, 2019 (Actual)
Study Completion Date
November 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nova Scotia Health Authority
Collaborators
Canadian Cardiovascular Society

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study to assess feasibility to conduct a multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on the atrial substrate, which is involved in the development and maintenance of atrial fibrillation (AF).
Detailed Description
Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It is associated with a six-fold risk of stroke and a two-fold increase in mortality, the main cardiac reason for death one year after presenting to the emergency department with AF is heart failure. It results in high healthcare costs, recurrent ED visits and hospitalizations. The burden of disability associated with AF has been found to increase by 20% from 1990-2010. AF was also cited as one of the seven causes of death that has been increasing worldwide. Prevention of AF has not been a focus of past treatments and it is well known that elevated body mass index, hypertension, smoking, increased alcohol intake, lack of exercise and sleep apnea are risk factors for AF. There is a lack of randomized, multicenter data proving that a strategy of aggressive risk factor modification will prevent and modify AF. Upstream therapy for AF has been of considerable interest, and benefit has been demonstrated in primary prevention of AF. Catheter ablation has demonstrated success over current medical therapies for long-term rhythm control, but recurrence remains high, irrespective of ablation strategy. This study is a feasibility study to determine whether a complex and multi-component risk factor modification can be successfully implemented.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
Risk Factor Modification, Catheter ablation

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This will be a parallel group, open label randomized clinical trial, with blinded endpoint evaluation (PROBE design)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aggressive Risk Factor Control
Arm Type
Experimental
Arm Description
Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
Intervention Type
Behavioral
Intervention Name(s)
Aggressive Risk Factor Control
Intervention Description
1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5. 2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting). 3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise. 4) An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted. 5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%
Intervention Type
Other
Intervention Name(s)
Standard of Care
Intervention Description
Recommendations based on current guidelines
Primary Outcome Measure Information:
Title
adherence to the risk factor intervention
Description
80% compliance to each of the components: 150 minutes exercise/week, BP target as per CHEP guidelines, alcohol limits, smoking cessation, and sleep apnea therapy, hemoglobin A1C<6.5% at the end of follow up. If 80% of individuals can reach these 80% of the time, the adherence criteria will be met.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Feasibility of recruitment
Description
Recruitment of ≥2.8 patients/center/month over three centers, thereby completing recruitment in 6 months
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with symptomatic (CCS-SAF ≥2) recurrent paroxysmal or persistent nonvalvular atrial fibrillation despite rate control, desiring catheter ablation AND one of : BMI>27, BP>140/90 or history of hypertension, alcohol use > recommended limit, current smoking, diabetes with HgA1C>7%, physical inactivity (<150 minutes/week). (Definitions: Recurrent paroxysmal - at least 4 episodes of symptomatic AF in the prior 6 months, with or without cardioversion; Persistent AF lasting greater than 7 days but less than 3 years; AF must be documented on a Holter, rhythm strip or electrocardiogram within the last 24 months.) Exclusion Criteria: Permanent AF (AF lasting > 3 years) Prior catheter ablation for AF Left ventricular ejection fraction <30% Left atrial size > 5.5 cm NYHA IV heart failure Participation in a cardiac rehabilitation program within the last year Currently performing exercise training 150 minutes/week of moderate to vigorous physical activity Unable to exercise Unable to give informed consent Other noncardiovascular medical condition making 1 year survival unlikely
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ratika Parkash
Organizational Affiliation
Nova Scotia Health Authority
Official's Role
Principal Investigator
Facility Information:
Facility Name
QE II Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 3A7
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study

We'll reach out to this number within 24 hrs